Abstract:BackgroundPrevious findings on hydroxychloroquine (HCQ) use and the risk of arrhythmia are contradictory and low-level evidence-based results. Additional research is required to evaluate the safety profile of HCQ to arrhythmia in managing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).ObjectivesTo assess the association between HCQ initiation and risk of incident arrhythmia among newly diagnosed RA and SLE patients.MethodsAll patients with incident RA or SLE and no arrhythmic events or anti-arrhythmic medications and no HCQ use prior to disease index date in British Columbia, Canada, between January 1997 and March 2015 were identified using administrative databases. HCQ initiator and HCQ non-initiator groups were identified and matched 1:1 by propensity scores using baseline confounders on demographics including presence of RA or SLE disease and duration of disease prior to the index date of HCQ initiators or non-initiators, comorbidities, other medications, and healthcare utilization. Matching was done within the same calendar year to account for a potential secular trend in HCQ use and risk of arrhythmia. Outcomes were any new arrhythmias, atrial fibrillation, abnormal electrocardiogram including prolonged QT syndrome and conduction disorder, and other unspecified arrhythmias during follow-up. We used Cox proportional hazard models with death as a competing event to assess the association of HCQ initiation and the outcomes.ResultsWe identified 11,518 HCQ initiators (10,655 RA and 863 SLE patients, mean ± SD age 55.9 ± 15.1 years, 76.1% female) and 11,518 HCQ non-initiators (10,639 RA and 879 SLE patients, mean ± SD age 56.0 ± 16.2 years, 76.4% female) after 1:1 propensity score matching. Over the mean follow-up of eight years, there were 1,610 and 1,646 incident arrhythmias in the HCQ initiator and non-initiator groups, respectively. The crude incidence rates of arrhythmia were 17.5, and 18.1 per 1,000 person-years, respectively. Cumulative risk of incident arrhythmia remained similar for both groups. (Figure 1). Adjusted hazard ratio (aHR) of incident arrhythmia from the Cox proportional hazard model for HCQ initiators was 0.99 (95% CI: 0.92-1.06) compared to non-initiators (Table 1). The corresponding aHRs for HCQ initiators in subtypes of arrhythmia – atrial fibrillation, abnormal electrocardiogram, and other unspecified arrhythmias were 0.95 (95% CI: 0.84-1.06), 1.04 (95% CI: 0.87-1.26), and 0.96 (95% CI: 0.86-1.08), respectively.Table 1.Incident arrhythmias of any type among RA and SLE patients initiating HCQ prescription compared with HCQ non-initiatorsHCQ initiatorHCQ non-initiatorParticipants (number)11,51811,518Mean follow-up (years)8.007.89Events (number)1,6101,646Crude incidence rate per 1000 person-years17.4818.12Unadjusted HR (95% CI)0.98 (0.91-1.05)1.00 (reference)Adjusted# HR (95% CI)0.99 (0.92-1.06)1.00 (reference)Abbreviations: HCQ, hydroxychloroquine; HR, hazard ratio.#The multivariable Cox proportional hazard model was adjusted for baseline confounders on demographics, comorbidities, medications, and healthcare utilization.Figure 1.Cumulative risk of incident arrhythmias for HCQ initiators and non-initiators over the follow-up time.ConclusionThere is no increased risk of any type of arrhythmia among new users of HCQ in RA and SLE patients. We believe the results of this large cohort study will add to the confidence with which HCQ can be used in RA and SLE management.Disclosure of InterestsNone declared.

The Missed Culprit For A Complex Case Of Non-ischemic Cardiomyopathy

Hydroxychloroquine-induced cardiomyopathy: role of cardiac magnetic resonance for the diagnosis and follow-up of a very rare entity-a case report

From Prescription to Predicament: Hydroxychloroquine (Hcq)-Induced Cardiogenic Shock (CS)

Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

OP0039 RISK OF ARRHYTHMIA AMONG NEW USERS OF HYDROXYCHLOROQUINE: A LONGITUDINAL POPULATION-BASED COHORT STUDY ON NEWLY DIAGNOSED RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Hospitalization after hydroxychloroquine initiation in patients with heart failure with preserved ejection fraction and autoimmune disease

Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts.

Severe Hypertrophic Cardiomyopathy Associated With Hydroxychloroquine in a Young Woman With Systemic Lupus Erythematosus: A Case Report and Review of the Literature

Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19

Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters

Hydroxychloroquine: Pharmacokinetics and Toxicity

Hydroxychloroquine-related Retinal Toxicity

Complete Heart Block in a Patient Undergoing Combination Immune Checkpoint Inhibitor Therapy

Rare Case of Iatrogenic Myocardial Infarction Induced by Use of Pyridostigmine

Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus

HYPOCALCEMIC CARDIOMYOPATHY PRESENTING AS HEART FAILURE EXACERBATION DUE TO UNTREATED PRIMARY HYPOPARATHYROIDISM: A CASE REPORT

Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus

Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients

Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia